argenx SE (LON:0QW0)

Market Cap	31.16B
Revenue (ttm)	2.28B
Net Income (ttm)	934.56M
Shares Out	n/a
EPS (ttm)	13.68
PE Ratio	33.35
Forward PE	32.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,975
Average Volume	13,029
Open	582.90
Previous Close	593.70
Day's Range	572.00 - 588.70
52-Week Range	435.40 - 656.80
Beta	0.03
RSI	85.56
Earnings Date	Jul 31, 2025

About Revance Therapeutics

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,599
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QW0